Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity
Comparing SARS-CoV-2 infection-induced gene expression signatures to drug treatment-induced gene expression signatures is a promising bioinformatic tool to repurpose existing drugs against SARS-CoV-2. The general hypothesis of signature-based drug repurposing is that drugs with inverse similarity to...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , |
---|---|
Dokumenttyp: | Article (Journal) |
Sprache: | Englisch |
Veröffentlicht: |
April 11, 2022
|
In: |
PLoS Computational Biology
Year: 2022, Jahrgang: 18, Heft: 4, Pages: 1-20 |
ISSN: | 1553-7358 |
DOI: | 10.1371/journal.pcbi.1010021 |
Online-Zugang: | kostenfrei kostenfrei ![]() |
Verfasserangaben: | Szilvia Barsi, Henrietta Papp, Alberto Valdeolivas, Dániel J. Tóth, Anett Kuczmog, Mónika Madai, László Hunyady, Péter Várnai, Julio Saez-Rodriguez, Ferenc Jakab, Bence Szalai |
Zusammenfassung: | Comparing SARS-CoV-2 infection-induced gene expression signatures to drug treatment-induced gene expression signatures is a promising bioinformatic tool to repurpose existing drugs against SARS-CoV-2. The general hypothesis of signature-based drug repurposing is that drugs with inverse similarity to a disease signature can reverse disease phenotype and thus be effective against it. However, in the case of viral infection diseases, like SARS-CoV-2, infected cells also activate adaptive, antiviral pathways, so that the relationship between effective drug and disease signature can be more ambiguous. To address this question, we analysed gene expression data from in vitro SARS-CoV-2 infected cell lines, and gene expression signatures of drugs showing anti-SARS-CoV-2 activity. ... |
---|---|
Beschreibung: | Gesehen am 07.11.2023 |
Beschreibung: | Online Resource |
ISSN: | 1553-7358 |
DOI: | 10.1371/journal.pcbi.1010021 |